Trial reportJournal of microbiology (Seoul, Korea)2022
A split face study on the effect of an anti-acne product containing fermentation products of Enterococcus faecalis CBT SL-5 on skin microbiome modification and acne improvement.
Trial report in Journal of microbiology (Seoul, Korea), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prebiotics, Probiotics, and Postbiotics for Acne Vulgaris: A Systematic Review.Dermatology and therapy · 2026Pooled it
- Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Using probiotics to treat acne vulgaris: systematic review.Archives of dermatological research · 2024Pooled it
- The Skin-Brain-Exposome Axis in Stress-Sensitive Dermatoses: A Narrative Review.Journal of clinical medicine · 2026Review
- Postbiotics in Dermatology: A Literature Review of Emerging Topical Therapies for Acne, Rosacea, and Eczema.Cureus · 2026Review
- Microbiome-Derived Indole-3-Lactic Acid AttenuatesInternational journal of molecular sciences · 2026Article
- Integrated Metagenomic and Lipidomic Profiling Reveals Dysregulation of Facial Skin Microbiome in Moderate Acne Vulgaris.Microorganisms · 2025Article
- Analysis of global trends and hotspots of skin microbiome in acne: a bibliometric perspective.BioData mining · 2025Article
- Acne vulgaris: advances in pathogenesis and prevention strategies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Efficacy of a Postbiotic Formulation Combined With Microneedling for Mild-to-Moderate Acne: A Self-Control Study.Journal of cosmetic dermatology · 2025Article
- Efficacy of Probiotic Supplements and Topical Applications in the Treatment of Acne: A Scoping Review of Current Results.Journal of experimental pharmacology · 2025Review
- Skin Microbiome in Health and Disease: Mechanisms and Emerging Therapeutic Strategies.Clinical, cosmetic and investigational dermatology · 2025Review
- Skin Deep: The Potential of Microbiome Cosmetics.Journal of microbiology (Seoul, Korea) · 2024Review
- The updates and implications of cutaneous microbiota in acne.Cell & bioscience · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic-resistant Cutibacterium acnes and dysbiosis of the skin microbiome are of increasing concern in acne treatment. Enterococcus faecalis, a widely used probiotic, has shown benefits for acne treatment by exerting antimicrobial activity against C. acnes. Therefore, this study aimed to investigate the efficacy and safety of an E. faecalis CBT SL-5-extract-containing lotion in patients with mild-to-moderate acne. Twenty patients were enrolled in this randomized, placebo-controlled, split-face comparative study. Patients were treated with E. faecalis lotion on one side of the face and a vehicle lotion on the other side for 4 weeks. The efficacy outcome measures included improvement in the investigators' assessment of acne severity, patient satisfaction, changes in skin parameters and diversity of the skin microbiome. The investigators' assessment score was significantly improved on the test side compared to the control side, after 2 weeks (p = 0.009) and 6 weeks (p < 0.0005). However, TEWL and skin hydration were not significantly different between the two groups. The phylogenetic diversity of the skin microbiota decreased over time in the skin samples of test side. In conclusion, E. faecalis CBT SL-5 extract can be a feasible and well-tolerated option for improving acne severity and skin microbiome dysbiosis in mild-to-moderate acne patients.
Indexed as
Identifiers
35286606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.